|
humans |
29 |
|
in vitro fertilization |
28 |
|
infertility |
27 |
|
female |
25 |
|
pregnancy |
25 |
|
ivf |
20 |
|
polycystic ovary syndrome |
18 |
|
endometrial receptivity |
16 |
|
adult |
15 |
|
embryo implantation |
15 |
|
male |
15 |
|
vitamin d |
15 |
|
ovarian response |
14 |
|
frozen embryo transfer |
13 |
|
miscarriage |
13 |
|
tubal ectopic pregnancy |
13 |
|
anti-mullerian hormone |
12 |
|
anti-müllerian hormone |
12 |
|
antral follicle count |
12 |
|
dysglycaemia |
12 |
|
fallopian tube |
12 |
|
pregnancy rate |
12 |
|
misoprostol |
11 |
|
pregnancy outcome |
11 |
|
reproductive medicine |
11 |
|
acrosome reaction |
10 |
|
implantation |
10 |
|
ovarian reserve |
10 |
|
cumulative live birth rate |
9 |
|
embryo transfer |
9 |
|
endometrial stem cells |
9 |
|
hyaluronic acid |
9 |
|
olfactomedin-1 |
9 |
|
ovulation induction |
9 |
|
wnt-signaling |
9 |
|
zona pellucida |
9 |
|
adrenomedullin |
8 |
|
adrenomedullin - genetics - metabolism |
8 |
|
calcitonin receptor-like protein |
8 |
|
cell communication - physiology |
8 |
|
cell line |
8 |
|
chinese |
8 |
|
chinese women |
8 |
|
cilia - metabolism - physiology |
8 |
|
cryopreservation |
8 |
|
embryo development |
8 |
|
endometrium |
8 |
|
epithelium - metabolism - physiology |
8 |
|
fallopian tubes - metabolism |
8 |
|
fertilization in vitro |
8 |
|
first trimester |
8 |
|
frozen-thawed embryo transfer |
8 |
|
gene expression regulation - drug effects |
8 |
|
glycodelin |
8 |
|
hormones - metabolism - pharmacology |
8 |
|
intracellular signaling peptides and proteins - genetics - metabolism |
8 |
|
live birth rate |
8 |
|
membrane proteins - genetics - metabolism |
8 |
|
menstrual cycle - genetics - metabolism - physiology |
8 |
|
mifepristone |
8 |
|
models, biological |
8 |
|
ovarian stimulation |
8 |
|
receptor activity-modifying proteins |
8 |
|
receptors, calcitonin - genetics - metabolism |
8 |
|
spermatozoa - metabolism - physiology |
8 |
|
stimulated cycles |
8 |
|
acupuncture |
7 |
|
age |
7 |
|
age‐specific reference range |
7 |
|
anti‐müllerian hormone |
7 |
|
automated chemiluminescence assay |
7 |
|
bioactive compounds |
7 |
|
chemokines |
7 |
|
ciliary beat frequency |
7 |
|
counseling |
7 |
|
counselling |
7 |
|
emergency contraception |
7 |
|
endometrial regeneration |
7 |
|
extraction |
7 |
|
glycoproteins - metabolism |
7 |
|
glycosylation |
7 |
|
hong kong |
7 |
|
inflammatory cytokines |
7 |
|
intrauterine insemination |
7 |
|
medical sciences |
7 |
|
metabolic syndrome |
7 |
|
multiple reaction monitoring |
7 |
|
nasal ciliated epithelium |
7 |
|
obstetrics and gynecology |
7 |
|
oocyte retrieval |
7 |
|
ovarian sensitivity index |
7 |
|
pain relief |
7 |
|
poor ovarian response |
7 |
|
pregnancy proteins - metabolism |
7 |
|
progesterone |
7 |
|
prospective studies |
7 |
|
spermatozoa |
7 |
|
subfertility |
7 |
|
tumor‐shrinking decoction |
7 |
|
ultra‐pressure liquid chromatography coupled tandem mass spectrometry |
7 |
|
wnt proteins - physiology |
7 |
|
advanced glycation end-products |
6 |
|
alpha-macroglobulins - metabolism |
6 |
|
angiogenesis |
6 |
|
apoptosis |
6 |
|
attitude |
6 |
|
cell biology |
6 |
|
cell signaling |
6 |
|
cell-signaling pathways |
6 |
|
chemotherapy |
6 |
|
chromatography, liquid |
6 |
|
chromosome deletion |
6 |
|
conscious sedation |
6 |
|
cumulus cells - metabolism |
6 |
|
cumulus matrix |
6 |
|
eg-vegf |
6 |
|
embryo attachment |
6 |
|
extracellular matrix proteins - metabolism |
6 |
|
extracellular matrix proteins - physiology |
6 |
|
fallopian tubes - cytology - metabolism |
6 |
|
fasting glucose |
6 |
|
female reproductive tract |
6 |
|
gestational trophoblastic neoplasia |
6 |
|
glycoproteins - physiology |
6 |
|
hippo signaling |
6 |
|
homozygote |
6 |
|
human embryonic stem cells |
6 |
|
human endometrium |
6 |
|
hyaluronic acid - metabolism |
6 |
|
in vitro implantation model |
6 |
|
in-vitro fertilization |
6 |
|
intracytoplasmic sperm injection |
6 |
|
letrozole |
6 |
|
male infertility |
6 |
|
mapk signaling |
6 |
|
mass spectrometry |
6 |
|
maternal immune tolerance |
6 |
|
medical abortion |
6 |
|
molar pregnancy |
6 |
|
oocytes - physiology |
6 |
|
oral glucose tolerance test |
6 |
|
pkr1 |
6 |
|
pkr2 |
6 |
|
pregnancy outcomes |
6 |
|
pregnancy, tubal - physiopathology |
6 |
|
progesterone receptor |
6 |
|
protein isoforms - metabolism |
6 |
|
randomized controlled trial |
6 |
|
soluble receptor of advanced glycation end-products |
6 |
|
sperm injections, intracytoplasmic |
6 |
|
sperm motility |
6 |
|
spermatozoa - metabolism |
6 |
|
stem cell-microenvironment interactions |
6 |
|
stem cells |
6 |
|
steroid receptors |
6 |
|
stromal cells |
6 |
|
threatened miscarriage |
6 |
|
time factors |
6 |
|
trophoblast |
6 |
|
trophoblastic spheroids |
6 |
|
trophoblasts |
6 |
|
ulipristal acetate |
6 |
|
utmvec-myo |
6 |
|
wnt signaling |
6 |
|
α2-macroglobulin |
6 |
|
25-hydroxyvitamin d |
5 |
|
adiposity |
5 |
|
adolescent |
5 |
|
androgen |
5 |
|
aneuploidy |
5 |
|
angiopoietin |
5 |
|
anti-mullerian hormone - blood |
5 |
|
anti‐mullerian hormone |
5 |
|
asian continental ancestry group |
5 |
|
assisted reproduction |
5 |
|
attachment |
5 |
|
biochemical profile |
5 |
|
biological markers - blood |
5 |
|
birth control medical sciences |
5 |
|
body-mind-spirit |
5 |
|
cancer |
5 |
|
choristoma - metabolism - pathology |
5 |
|
ciliary beat |
5 |
|
cytokines |
5 |
|
down syndrome |
5 |
|
down syndrome - blood |
5 |
|
embryo cryopreservation |
5 |
|
embryo implantation - genetics |
5 |
|
embryo quality |
5 |
|
embryo research - legislation & jurisprudence |
5 |
|
embryo, mammalian |
5 |
|
endocrine glands |
5 |
|
endocrinology pharmacy and pharmacology |
5 |
|
endometrial attachment |
5 |
|
endometriosis |
5 |
|
endometriosis - metabolism - pathology |
5 |
|
endometrium - drug effects - metabolism |
5 |
|
endometrium - pathology |
5 |
|
endothelial cell |
5 |
|
fertility preservation |
5 |
|
fertilization |
5 |
|
fucosyltransferase |
5 |
|
gestational age |
5 |
|
glycodelin-a |
5 |
|
gonadotrophin dosing |
5 |
|
hcg |
5 |
|
human fallopian tube |
5 |
|
hydrosalpinx |
5 |
|
in vitro fertilsation |
5 |
|
infection |
5 |
|
infectious disease transmission, vertical |
5 |
|
intercellular signaling peptides and proteins - biosynthesis |
5 |
|
ishikawa cell line |
5 |
|
l-selectin |
5 |
|
laser-captured microdissection |
5 |
|
live birth |
5 |
|
macrophage |
5 |
|
maternal age |
5 |
|
membrane protein |
5 |
|
microarray |
5 |
|
middle aged |
5 |
|
monocyte |
5 |
|
muscular contraction |
5 |
|
natural cycle |
5 |
|
natural cycles |
5 |
|
natural killer cell |
5 |
|
obstetrics and gynecology medical sciences |
5 |
|
oestrogen |
5 |
|
oestrogen receptor |
5 |
|
oocyte cryopreservation |
5 |
|
oral progestogen |
5 |
|
ovarian response prediction index |
5 |
|
ovarian stromal blood flow |
5 |
|
ovulation induction - adverse effects |
5 |
|
ovulation induction - adverse effects - methods |
5 |
|
paep |
5 |
|
pd-l1 |
5 |
|
pk1 |
5 |
|
placental exosome |
5 |
|
polymerase chain reaction |
5 |
|
preeclampsia |
5 |
|
pregnancy - blood |
5 |
|
preimplantation diagnosis |
5 |
|
preimplantation genetic testing |
5 |
|
prenatal diagnosis |
5 |
|
primary endometrial cell culture |
5 |
|
progestagen-associated endometrial protein |
5 |
|
progesterone elevation |
5 |
|
protein disulphide isomerase |
5 |
|
psychosocial intervention |
5 |
|
pten |
5 |
|
reference values |
5 |
|
reproductive techniques, assisted - ethics - legislation & jurisprudence - standards |
5 |
|
semen |
5 |
|
semen analysis |
5 |
|
sperm cryopreservation |
5 |
|
spheroid attachment |
5 |
|
spheroids |
5 |
|
steroid hormones |
5 |
|
t cell |
5 |
|
transfer medium |
5 |
|
up-regulation - physiology |
5 |
|
vaginal bleeding |
5 |
|
vascular endothelial growth factor, endocrine-gland-derived - biosynthesis |
5 |
|
vegf |
5 |
|
abortifacient agents, nonsteroidal - administration & dosage - adverse effects |
4 |
|
abortifacient agents, nonsteroidal - pharmacokinetics |
4 |
|
abortion, induced |
4 |
|
abortion, induced - methods |
4 |
|
acceptance |
4 |
|
acetic acid |
4 |
|
acetic acid - pharmacokinetics |
4 |
|
adhesions |
4 |
|
afc |
4 |
|
afp |
4 |
|
alleles |
4 |
|
allergology and immunology medical sciences |
4 |
|
alpha-fetoprotein |
4 |
|
alpha-thalassemia - diagnosis - embryology - genetics |
4 |
|
alpha-thalassemia - diagnosis - genetics |
4 |
|
amino acid sequence |
4 |
|
amniotic fluid |
4 |
|
androgen receptor |
4 |
|
anti-mullerian hormone - analysis - blood |
4 |
|
anti-möllerian hormone |
4 |
|
antimullerian hormone |
4 |
|
art |
4 |
|
asians |
4 |
|
assisted reproductive technologies |
4 |
|
assisted reproductive technology |
4 |
|
automated chemiluminescence |
4 |
|
beta-thalassemia - diagnosis - genetics |
4 |
|
birth control |
4 |
|
blastocyst - metabolism |
4 |
|
blastomere |
4 |
|
blastomeres |
4 |
|
body weight |
4 |
|
bologna criteria |
4 |
|
cag repeat |
4 |
|
case-control studies |
4 |
|
cell surface proteins |
4 |
|
cesarean section - adverse effects |
4 |
|
cftr |
4 |
|
china |
4 |
|
chinese couple |
4 |
|
chinese culture |
4 |
|
chorionic gonadotropin, beta subunit, human - blood |
4 |
|
chromatin methylation |
4 |
|
chromosome, human, y |
4 |
|
cicatrix - complications - pathology |
4 |
|
clinical pregnancy |
4 |
|
combined injectable contraceptive |
4 |
|
combined oral contraceptive |
4 |
|
concern |
4 |
|
contraceptives, oral, combined - pharmacology |
4 |
|
controlled ovarian stimulation |
4 |
|
cumulative live birth |
4 |
|
cumulative live-birth |
4 |
|
cytokine |
4 |
|
definitive endoderm |
4 |
|
dehydroepiandrosterone |
4 |
|
deletion |
4 |
|
dhea |
4 |
|
dilution linearity |
4 |
|
diminished ovarian reserve |
4 |
|
dna integrity |
4 |
|
dna meiotic recombinase 1 (dmc1) |
4 |
|
dna primers - genetics |
4 |
|
dna, mitochondrial - genetics - isolation & purification |
4 |
|
doppler |
4 |
|
down syndrome - blood - diagnosis |
4 |
|
down's syndrome |
4 |
|
dydrogesterone |
4 |
|
embryo implantation - genetics - physiology |
4 |
|
endocrinology |
4 |
|
endometrial and subendometrial vascularity |
4 |
|
endometrial injury |
4 |
|
endometrial polyp |
4 |
|
endometrium - metabolism |
4 |
|
enzyme-linked immunosorbent assay |
4 |
|
erk |
4 |
|
estradiol - blood |
4 |
|
etu |
4 |
|
exosomes |
4 |
|
expanded carrier screening |
4 |
|
extracellular matrix proteins - chemistry - genetics - metabolism |
4 |
|
extracellular small non-coding rnas |
4 |
|
family planning service provision |
4 |
|
fet |
4 |
|
fetomaternal tolerance |
4 |
|
follicle |
4 |
|
follicle stimulating hor mone/administration & dosage |
4 |
|
follicle stimulating hormone/therapeutic use |
4 |
|
follicle-stimulating hormone |
4 |
|
freeze-thaw stability |
4 |
|
gender ratio |
4 |
|
gender selection |
4 |
|
gene expression regulation, developmental - genetics |
4 |
|
genetic predisposition to disease |
4 |
|
gestational diabetes mellitus |
4 |
|
glycoprotein |
4 |
|
glycoproteins - chemistry - genetics - metabolism |
4 |
|
gonadotropins/administration & dosage |
4 |
|
gonadotropins/therapeutic use |
4 |
|
granulosa cells |
4 |
|
green tea |
4 |
|
growth |
4 |
|
gynecological diseases |
4 |
|
hescs |
4 |
|
homozygous a° thal |
4 |
|
homozygous frameshift mutation |
4 |
|
hormonal profile |
4 |
|
hspa2 |
4 |
|
human chorionic gonadotrophin |
4 |
|
human spermatozoa |
4 |
|
human study |
4 |
|
hydatidiform mole - diagnosis - etiology - therapy |
4 |
|
hydrogen-ion concentration |
4 |
|
hyperglycemia |
4 |
|
hyperprolactinemia |
4 |
|
hypogonadotrophic hypogonadism |
4 |
|
hysteroscopy |
4 |
|
icsi |
4 |
|
immunoassay |
4 |
|
in vitro activation |
4 |
|
in vitro fertilisation |
4 |
|
in-vitro fertilisation |
4 |
|
infertility - blood - diagnosis - therapy |
4 |
|
infertility, female - genetics |
4 |
|
infertility, female - therapy |
4 |
|
infertility, male |
4 |
|
inhibin b |
4 |
|
inhibins - blood |
4 |
|
insemination, artificial - methods |
4 |
|
interleukin 6 |
4 |
|
intervention |
4 |
|
intrauterine devices, medicated |
4 |
|
intrauterine lidocaine |
4 |
|
isolated polycystic ovaries |
4 |
|
ivf-embryo transfer |
4 |
|
lactobacillus |
4 |
|
letrozole pretreatment |
4 |
|
levonorgestrel intrauterine system |
4 |
|
lidocaine gel |
4 |
|
live-birth |
4 |
|
luteal phase |
4 |
|
luteal phase support |
4 |
|
macrophages |
4 |
|
male germline-specific protein |
4 |
|
male preference |
4 |
|
mancozeb |
4 |
|
maps |
4 |
|
meaning making |
4 |
|
meiosis prophase i |
4 |
|
menstrual cycle |
4 |
|
menstrual cycle - physiology |
4 |
|
mental health |
4 |
|
method comparison |
4 |
|
methylation |
4 |
|
micrornas - genetics - metabolism |
4 |
|
misoprostol - administration & dosage - adverse effects |
4 |
|
misoprostol - pharmacokinetics |
4 |
|
mitochondrial dna copy number |
4 |
|
monocytes |
4 |
|
mouse study |
4 |
|
mutation |
4 |
|
natural family planning |
4 |
|
non-invasive biomarker |
4 |
|
nonobstructive azoospermia |
4 |
|
normal ovarian responders |
4 |
|
normal saline |
4 |
|
nt |
4 |
|
nuchal translucency |
4 |
|
obstetrics |
4 |
|
olfactomedin |
4 |
|
oligomenorrhea - blood - diagnosis - etiology |
4 |
|
oocyte |
4 |
|
oogenesis |
4 |
|
osmolar concentration |
4 |
|
ovarian response markers |
4 |
|
ovary - drug effects |
4 |
|
ovary/drug effects |
4 |
|
ovulation induction - methods |
4 |
|
pachynema progression |
4 |
|
papp-a |
4 |
|
pcr |
4 |
|
pgd |
4 |
|
pharmacokinetics |
4 |
|
pi3k/pten signaling |
4 |
|
placenta |
4 |
|
placentation |
4 |
|
poor responders |
4 |
|
population control |
4 |
|
precision |
4 |
|
predictive value of tests |
4 |
|
pregnancy trimester, first - blood |
4 |
|
pregnancy trimester, second |
4 |
|
pregnancy-associated plasma protein-a - metabolism |
4 |
|
preimplantation diagnosis - methods |
4 |
|
premature ovarian failure |
4 |
|
premature ovarian insufficiency |
4 |
|
primordial follicles |
4 |
|
progestins - pharmacology |
4 |
|
progestogen |
4 |
|
progestogen-only injectable |
4 |
|
progestogen-only pill |
4 |
|
protamination |
4 |
|
quality of life |
4 |
|
questionnaires |
4 |
|
randomised trial |
4 |
|
receptivity marker |
4 |
|
repeated implantation failure |
4 |
|
reproductive techniques, assisted |
4 |
|
saline contrast sonohysterography |
4 |
|
saline infusion sonogram |
4 |
|
second trimester |
4 |
|
sequence deletion |
4 |
|
sexual dimorphism |
4 |
|
short-chain fatty acids |
4 |
|
sialic acid |
4 |
|
spaca3 |
4 |
|
sperm |
4 |
|
sperm selection |
4 |
|
spermatogenesis |
4 |
|
stem cell niche |
4 |
|
steroid hormone receptors |
4 |
|
steroid regulation |
4 |
|
stimulated cycle |
4 |
|
sublingual |
4 |
|
survey |
4 |
|
t-cell |
4 |
|
termination of pregnancy |
4 |
|
testosterone |
4 |
|
thalassaemia |
4 |
|
three-dimensional power doppler |
4 |
|
three-dimensional ultrasound |
4 |
|
transcutaneous electrical nerve stimulation |
4 |
|
transvaginal oocyte retrieval |
4 |
|
twins |
4 |
|
unfertilized oocyte |
4 |
|
uterine neoplasms - diagnosis - etiology - therapy |
4 |
|
vaginal misoprostol |
4 |
|
whole-exome sequencing |
4 |
|
wnt/β-catenin signaling |
4 |
|
wnt/β-catenin signaling pathway |
4 |
|
3d power doppler |
3 |
|
4930432k21rik |
3 |
|
abortifacient agents - administration and dosage |
3 |
|
abortifacient agents, steroidal - administration & dosage - adverse effects |
3 |
|
abortion, induced - methods - standards |
3 |
|
acrosome reaction - drug effects |
3 |
|
adverse pregnancy outcomes |
3 |
|
andrology |
3 |
|
androstenedione - metabolism |
3 |
|
animals |
3 |
|
anxiety |
3 |
|
aric |
3 |
|
aromatase inhibitors - administration and dosage - therapeutic use |
3 |
|
arteries - physiopathology |
3 |
|
arthritis |
3 |
|
arthritis, rheumatoid |
3 |
|
artificial insemination |
3 |
|
assisted hatching |
3 |
|
azf |
3 |
|
biopsy |
3 |
|
bisphenols |
3 |
|
blast analysis |
3 |
|
body mass index |
3 |
|
brca2 novel deletion |
3 |
|
breast cancer |
3 |
|
c-terminal binding protein 1 |
3 |
|
ca-125 |
3 |
|
ca-125 antigen - metabolism |
3 |
|
calcium ionophore |
3 |
|
casa |
3 |
|
cells, cultured |
3 |
|
china - epidemiology |
3 |
|
chlamydia trachomatis |
3 |
|
chorionic gonadotropin - administration & dosage |
3 |
|
chorionic gonadotropin - administration & dosage - therapeutic use |
3 |
|
chorionic gonadotropin - therapeutic use |
3 |
|
chromosomes, human, y - genetics |
3 |
|
chronic inflammation |
3 |
|
cleavage stage embryo |
3 |
|
clomiphene - pharmacology |
3 |
|
co-culture |
3 |
|
cohort studies |
3 |
|
color signals |
3 |
|
complications |
3 |
|
computer-aided sperm analysis |
3 |
|
conditioned medium |
3 |
|
consensus development study |
3 |
|
continuous companion support |
3 |
|
contraceptives |
3 |
|
contraceptives, oral, combined |
3 |
|
contraceptives, oral, hormonal |
3 |
|
coping |
3 |
|
core outcome sets |
3 |
|
corifollitropin alfa |
3 |
|
cost |
3 |
|
covid-19 pandemic |
3 |
|
culture media, conditioned - pharmacology |
3 |
|
cycle-to-cycle variation |
3 |
|
cystic fibrosis transmembrane conductance regulator - genetics - immunology - metabolism |
3 |
|
data entry |
3 |
|
data precision |
3 |
|
decidualization |
3 |
|
decision-making |
3 |
|
decisional conflicts |
3 |
|
decisional regret |
3 |
|
diagnosis, computer-assisted |
3 |
|
dna - chemistry - genetics |
3 |
|
doppler haemodynamics |
3 |
|
doppler hemodynamics |
3 |
|
dose-response relationship, drug |
3 |
|
double-blind method |
3 |
|
early pregnancy |
3 |
|
early pregnancy assessment clinic |
3 |
|
ectopic pregnancy |
3 |
|
embryo |
3 |
|
embryo transfer - statistics & numerical data |
3 |
|
embryonic and fetal development - drug effects |
3 |
|
endometrial and subendometrial blood flow |
3 |
|
endometrial and subendometrial blood flows |
3 |
|
endometrial blood flow |
3 |
|
endometrial morphometry |
3 |
|
endometrial perfusion |
3 |
|
endometrial vascularity |
3 |
|
endometrium - blood supply |
3 |
|
endometrium - chemistry |
3 |
|
endometrium - drug effects - ultrasonography |
3 |
|
endometrium - metabolism - ultrasonography |
3 |
|
endometrium - ultrasonography |
3 |
|
epithelial cells - pathology |
3 |
|
epithelial cells - ultrastructure |
3 |
|
epithelial damage |
3 |
|
erectile dysfunction |
3 |
|
estradiol |
3 |
|
estrogen |
3 |
|
ethnicity |
3 |
|
excessive ovarian responses |
3 |
|
excessive responders |
3 |
|
fallopian tube diseases - complications - genetics - pathology |
3 |
|
fallopian tube diseases - complications - pathology |
3 |
|
fallopian tube diseases - pathology |
3 |
|
fallopian tube patency tests - methods |
3 |
|
fallopian tubes - pathology |
3 |
|
female sexual dysfunction |
3 |
|
fertile women |
3 |
|
fertility restoration |
3 |
|
fertilization in vitro - methods |
3 |
|
fet cycles |
3 |
|
fibroids |
3 |
|
first trimester medical abortions |
3 |
|
follicle stimulating hormone - administration & dosage - adverse effects |
3 |
|
follicle stimulating hormone - blood |
3 |
|
follicular fluid |
3 |
|
forecasting |
3 |
|
frozen thawed embryo transfer |
3 |
|
fsh/administration & dosage |
3 |
|
gene expression regulation |
3 |
|
gestational diabetes |
3 |
|
gnrh antagonist |
3 |
|
gratitude |
3 |
|
group psychotherapy |
3 |
|
hemodynamics |
3 |
|
hepatitis b |
3 |
|
hepatitis b surface antigen |
3 |
|
hepatitis b surface antigens - analysis |
3 |
|
hepatitis b virus |
3 |
|
hepatitis b, chronic - physiopathology - transmission |
3 |
|
high oestradiol |
3 |
|
high responders |
3 |
|
hmg |
3 |
|
holistic health |
3 |
|
hormonal |
3 |
|
hormonal control |
3 |
|
hormone profile |
3 |
|
hormone replacement therapy |
3 |
|
huntington disease |
3 |
|
hydrosalpinx fluid |
3 |
|
hysterosalpingography |
3 |
|
immunoprophylaxis failure |
3 |
|
implantation rate |
3 |
|
in vitro fertilization/embryo transfer |
3 |
|
infectious disease transmission |
3 |
|
infertility - drug therapy - metabolism |
3 |
|
infertility - therapy |
3 |
|
infertility in-vitro fertilization |
3 |
|
infertility, female |
3 |
|
infertility, female - blood - drug therapy - physiopathology |
3 |
|
infertility, female - diagnosis |
3 |
|
infertility, female - etiology - pathology |
3 |
|
infertility, female - genetics - pathology |
3 |
|
infertility, male - epidemiology - genetics |
3 |
|
infertility, male - genetics |
3 |
|
injections, intramuscular |
3 |
|
insemination |
3 |
|
insemination, artificial |
3 |
|
insemination, artificial, homologous |
3 |
|
insemination, artificial, husband |
3 |
|
intercycle variation |
3 |
|
interleukin-11 - analysis |
3 |
|
interleukin-4 - analysis |
3 |
|
interleukin-6 - analysis |
3 |
|
intramuscular |
3 |
|
invasion |
3 |
|
isolate |
3 |
|
ivf patients |
3 |
|
ivf treatment |
3 |
|
ixaprep |
3 |
|
labour |
3 |
|
laparoscopy |
3 |
|
laparoscopy - methods |
3 |
|
laser |
3 |
|
laser assisted hatching |
3 |
|
leukemia inhibitory factor |
3 |
|
live-birth rate |
3 |
|
logistic models |
3 |
|
lupus erythematosus |
3 |
|
lupus erythematosus, systemic |
3 |
|
luteinizing hormone - blood |
3 |
|
maternal-embryo communication |
3 |
|
meiosis |
3 |
|
menotropins - administration & dosage |
3 |
|
menotropins - administration and dosage - therapeutic use |
3 |
|
menstrual pattern |
3 |
|
mice - embryology |
3 |
|
mice, inbred icr |
3 |
|
microrna |
3 |
|
microscopy |
3 |
|
microscopy, electron |
3 |
|
microscopy, electron, scanning |
3 |
|
mifepristone - administration & dosage - adverse effects |
3 |
|
mifepristone - administration and dosage |
3 |
|
mir-212 |
3 |
|
misoprostol - administration and dosage |
3 |
|
morphology |
3 |
|
mosaicism |
3 |
|
motile sperm recovery |
3 |
|
multiple pregnancy rate |
3 |
|
nausea and vomiting in pregnancy |
3 |
|
nitriles - administration and dosage |
3 |
|
nitriles - administration and dosage - therapeutic use |
3 |
|
non-obstructive azoospermia |
3 |
|
number of embryos replaced |
3 |
|
nurses |
3 |
|
obese |
3 |
|
oestradiol |
3 |
|
ohss |
3 |
|
olfactomedin 1 |
3 |
|
oligospermia - epidemiology - genetics |
3 |
|
oligospermia - genetics |
3 |
|
oocyte and embryo quality |
3 |
|
oocyte quality |
3 |
|
oral |
3 |
|
outcome assessment (health care) |
3 |
|
outcome measures |
3 |
|
outgrowth |
3 |
|
ovarian stimulation syndrome |
3 |
|
ovarian volume |
3 |
|
ovary |
3 |
|
ovary - blood supply |
3 |
|
pain measurement |
3 |
|
patient-centred care |
3 |
|
pdi |
3 |
|
pdi inhibitors |
3 |
|
percoll |
3 |
|
perifollicular vascularity |
3 |
|
pituitary downregulation |
3 |
|
placebo |
3 |
|
polycystic ovaries |
3 |
|
poor ovarian responders |
3 |
|
poor ovarian responses |
3 |
|
post-ovulatory |
3 |
|
power doppler |
3 |
|
pp14 |
3 |
|
pre-ovulatory |
3 |
|
preconception |
3 |
|
pregnancy - statistics & numerical data |
3 |
|
probability |
3 |
|
problem solving |
3 |
|
prognosis |
3 |
|
psychological well-being |
3 |
|
public service |
3 |
|
pulsatile flow |
3 |
|
pulse |
3 |
|
quality of life. |
3 |
|
recombinant human fsh |
3 |
|
recombinant proteins - administration & dosage - adverse effects |
3 |
|
recombinant proteins/administration & dosage |
3 |
|
recombination |
3 |
|
regional blood flow |
3 |
|
reproduction |
3 |
|
reproduction techniques |
3 |
|
results |
3 |
|
retrospective cohort |
3 |
|
retrospective studies |
3 |
|
reverse transcriptase polymerase chain reaction |
3 |
|
rheumatic diseases |
3 |
|
rheumatoid |
3 |
|
rupture of membranes |
3 |
|
sampling studies |
3 |
|
second trimester medical abortion |
3 |
|
second-trimester medical abortion |
3 |
|
secretory phase endometrium |
3 |
|
semen - physiology |
3 |
|
sensitivity and specificity |
3 |
|
sequence tagged sites |
3 |
|
sex chromosome aberrations |
3 |
|
sexual abstinence |
3 |
|
specimen handling |
3 |
|
sperm haplotyping |
3 |
|
sperm motility - drug effects |
3 |
|
sperm separation |
3 |
|
spousal relationship |
3 |
|
statistics, nonparametric |
3 |
|
stimulation |
3 |
|
stimulation cycles |
3 |
|
stromal blood flow |
3 |
|
subcutaneous |
3 |
|
subendometrial blood flow |
3 |
|
suboptimal endometrium |
3 |
|
systemic |
3 |
|
testicular sperm extraction |
3 |
|
testosterone - blood |
3 |
|
th2 cells - metabolism |
3 |
|
therapeutic irrigation |
3 |
|
three-dimensional hysterosalpingo-contrast- sonography |
3 |
|
transvaginal ultrasound |
3 |
|
treatment decision-making |
3 |
|
treatment failure |
3 |
|
treatment outcome |
3 |
|
triazoles - administration and dosage - therapeutic use |
3 |
|
ubiquitination |
3 |
|
ultrasonography, doppler - methods |
3 |
|
ultrasonography, doppler, color |
3 |
|
ultrasonography, prenatal |
3 |
|
uterine blood flow |
3 |
|
uterine doppler flow |
3 |
|
uterine flushing |
3 |
|
uterus - blood supply |
3 |
|
vascular resistance |
3 |
|
vertical |
3 |
|
viral load |
3 |
|
virus immunization |
3 |
|
waiting time |
3 |
|
whole genome amplification |
3 |
|
willingness to pay |
3 |
|
y chromosome |
3 |
|
y chromosome microdeletion |
3 |
|
zona breaching and zona thinning |
3 |
|
3-dimensional power doppler ultrasonography |
2 |
|
3d |
2 |
|
abdominal pain - drug therapy |
2 |
|
abortifacient agents, steroidal - adverse effects - therapeutic use |
2 |
|
abortion, induced - statistics and numerical data |
2 |
|
administration, intravaginal |
2 |
|
administration, sublingual |
2 |
|
adult stem cells |
2 |
|
age factors |
2 |
|
ageing |
2 |
|
amh |
2 |
|
anesthesia, obstetrical |
2 |
|
anesthetics, local - administration & dosage - therapeutic use |
2 |
|
anovulation |
2 |
|
anovulatory subfertility |
2 |
|
anti-oestrogen |
2 |
|
antibiotics |
2 |
|
antibodies, bacterial/blood |
2 |
|
antral follicles |
2 |
|
aromatase inhibitor |
2 |
|
asia - epidemiology |
2 |
|
asian women |
2 |
|
atosiban |
2 |
|
automated assays |
2 |
|
body fluids - metabolism |
2 |
|
breakpoint |
2 |
|
cerclage |
2 |
|
cerebral cortex - blood supply |
2 |
|
cerebral hemorrhage |
2 |
|
cervical length |
2 |
|
chlamydia infections - complications - physiopathology |
2 |
|
chlamydia infections - metabolism - microbiology |
2 |
|
chlamydia trachomatis - isolation and purification |
2 |
|
chlamydia trachomatis antibody |
2 |
|
chlamydial infection |
2 |
|
circadian rhythm |
2 |
|
clomiphene |
2 |
|
clomiphene - therapeutic use |
2 |
|
clomiphene citrate |
2 |
|
clomiphene citrate challenge test |
2 |
|
clomiphene-resistant |
2 |
|
companion diagnostic |
2 |
|
congenital |
2 |
|
congenital abnormalities - etiology |
2 |
|
controlled ovarian hyperstimulation |
2 |
|
crinone |
2 |
|
cyclogest |
2 |
|
cystic fibrosis transmembrane conductance regulator - metabolism |
2 |
|
death |
2 |
|
dehydroepiandrosterone sulfate - blood |
2 |
|
delphi survey |
2 |
|
depression |
2 |
|
diagnosis, differential |
2 |
|
dichorionic |
2 |
|
dilation and evacuation |
2 |
|
dopamine agonist |
2 |
|
doppler ultrasound |
2 |
|
drug therapy, combination |
2 |
|
edema |
2 |
|
egg collection |
2 |
|
endometrial biopsy |
2 |
|
endometrial mesenchymal stromal/stem cells |
2 |
|
endometrial repair |
2 |
|
ethnic origin |
2 |
|
expectation |
2 |
|
extracellular vesicles |
2 |
|
fallopian tube diseases - complications - metabolism |
2 |
|
fallopian tube diseases - metabolism - microbiology |
2 |
|
fallopian tube diseases - pathology - surgery |
2 |
|
fallopian tube diseases - physiopathology |
2 |
|
fallopian tubes - surgery |
2 |
|
fertility |
2 |
|
fertility agents, female - therapeutic use |
2 |
|
fertilization in vitro - adverse effects - methods |
2 |
|
follicular vascularity |
2 |
|
follitropin delta |
2 |
|
fsh |
2 |
|
genetics |
2 |
|
gonadotrophin |
2 |
|
gonadotropins |
2 |
|
gonadotropins - therapeutic use |
2 |
|
gynaecology |
2 |
|
gynaecology and fertility |
2 |
|
haemorrhage |
2 |
|
haplotype |
2 |
|
herbal medicine |
2 |
|
human sperm |
2 |
|
hypoglycemic agents - therapeutic use |
2 |
|
hysterectomy |
2 |
|
iliac vein |
2 |
|
immunoassays |
2 |
|
implantation failure |
2 |
|
in vitro fertilisation (ivf) |
2 |
|
in vitro fertilization: pregnancy, three-dimensional ultrasound |
2 |
|
infertility, female - drug therapy - physiopathology |
2 |
|
infertility. |
2 |
|
insulin resistance |
2 |
|
insulin sensitivity |
2 |
|
intimate partner violence |
2 |
|
intracranial thrombosis - diagnosis - etiology |
2 |
|
intrauterine adhesion |
2 |
|
inversion |
2 |
|
ipd meta-analysis |
2 |
|
jag1 |
2 |
|
killer cells, natural - pathology |
2 |
|
knowledge |
2 |
|
levonorgestrel |
2 |
|
lgr5 |
2 |
|
lidocaine - administration & dosage - therapeutic use |
2 |
|
lignocaine |
2 |
|
long-read |
2 |
|
luteal phase - drug effects |
2 |
|
magnetic resonance imaging |
2 |
|
male subfertility |
2 |
|
maternal |
2 |
|
menstruation |
2 |
|
metformin |
2 |
|
mifepristone - adverse effects - therapeutic use |
2 |
|
miscarriages |
2 |
|
monochorionic |
2 |
|
mortality |
2 |
|
multiple doses |
2 |
|
n2o |
2 |
|
nanopore sequencing |
2 |
|
neonatal |
2 |
|
niche |
2 |
|
nipgt-a |
2 |
|
nitric oxide donor |
2 |
|
non-invasive |
2 |
|
notch signaling pathway |
2 |
|
obstetric outcomes |
2 |
|
oocytes |
2 |
|
outcomes |
2 |
|
ovarian cysts - etiology |
2 |
|
ovarian cysts - ultrasonography |
2 |
|
ovarian drilling |
2 |
|
ovarian follicle - ultrasonography |
2 |
|
ovarian function |
2 |
|
ovarian hyperstimulation syndrome - complications |
2 |
|
ovary - blood supply - metabolism - surgery |
2 |
|
ovary - blood supply - ultrasonography |
2 |
|
ovulation |
2 |
|
oxygen |
2 |
|
pain |
2 |
|
paracervical block |
2 |
|
patient convenience |
2 |
|
patient selection |
2 |
|
pcos |
2 |
|
perception |
2 |
|
perinatal transmission |
2 |
|
personalised medicine |
2 |
|
pgt-a |
2 |
|
pgt-sr |
2 |
|
pituitary gland - drug effects - physiopathology |
2 |
|
placebos |
2 |
|
polycystic ovary only |
2 |
|
polycystic ovary syndrome - diagnosis - ethnology - metabolism - therapy |
2 |
|
polycystic ovary syndrome - ultrasonography |
2 |
|
postcoital contraception |
2 |
|
postoperative side effects |
2 |
|
postoperative side-effects |
2 |
|
prediction of ovarian response |
2 |
|
pregnancy trimester, first |
2 |
|
pregnancy-induced hypertension |
2 |
|
preimplantation |
2 |
|
prematurity |
2 |
|
premedication |
2 |
|
preterm |
2 |
|
preterm birth |
2 |
|
progesterone - administration & dosage - pharmacology - therapeutic use |
2 |
|
pulsatile gnrh |
2 |
|
randomized control trials |
2 |
|
randomized trial |
2 |
|
reciprocal translocation |
2 |
|
regeneration |
2 |
|
reproductive techniques |
2 |
|
robertsonian |
2 |
|
rspo1 |
2 |
|
salpingectomy |
2 |
|
satisfaction level |
2 |
|
second trimester abortion |
2 |
|
severe ohss |
2 |
|
side effects |
2 |
|
single dose |
2 |
|
site of semen collection |
2 |
|
small-for-gestational age |
2 |
|
sodium nitroprusside |
2 |
|
spent culture media |
2 |
|
sperm dna fragmentation |
2 |
|
spouse abuse - psychology - statistics and numerical data |
2 |
|
stein-leventhal syndrome. |
2 |
|
stem cell |
2 |
|
stillbirth |
2 |
|
subendometrial vascularity |
2 |
|
suction evacuation |
2 |
|
suppositories - adverse effects |
2 |
|
surgical termination of pregnancy |
2 |
|
teratogens - metabolism |
2 |
|
three-dimensional power doppler ultrasonography |
2 |
|
thromboembolism |
2 |
|
tissue and organ harvesting - methods |
2 |
|
transabdominal ultrasound |
2 |
|
translocation |
2 |
|
tubal pathology |
2 |
|
ultrasonographic parameters |
2 |
|
ultrasound |
2 |
|
universal use |
2 |
|
unprotected intercourse |
2 |
|
uterine artery blood flow |
2 |
|
uterine contraction |
2 |
|
uterine fibroids |
2 |
|
vacuum curettage |
2 |
|
vagina |
2 |
|
vaginal |
2 |
|
vaginal creams, foams, and jellies - adverse effects |
2 |
|
vaginal progesterone |
2 |
|
varicella zoster virus |
2 |
|
vascular thrombosis |
2 |
|
vena cava, inferior |
2 |
|
venous thrombosis - diagnosis - etiology |
2 |
|
vertical transmission |
2 |
|
weight management |
2 |
|
who group ii anovulation |
2 |
|
wnt signalling |
2 |
|
abortifacient agents, nonsteroidal - administration and dosage |
1 |
|
abortifacient agents, steroidal - administration and dosage |
1 |
|
abortion, spontaneous - diagnosis |
1 |
|
acupuncture pretreatment |
1 |
|
acupuncture therapy |
1 |
|
acupuncture therapy - adverse effects |
1 |
|
adjuvant |
1 |
|
anesthetics, local - administration & dosage |
1 |
|
antimullerian horme |
1 |
|
antral folicle count |
1 |
|
berberine |
1 |
|
berberine - administration and dosage - adverse effects - therapeutic use |
1 |
|
blood glucose - drug effects - metabolism |
1 |
|
brief incubation |
1 |
|
chinese herbal medicine |
1 |
|
chlamydia antibody test |
1 |
|
chorionic gonadotropin - administration & dosage - adverse effects - pharmacology |
1 |
|
consensus science methods |
1 |
|
consort |
1 |
|
contraceptives, oral, synthetic - administration & dosage |
1 |
|
contraceptives, postcoital, synthetic - administration & dosage |
1 |
|
diagnostic accuracy |
1 |
|
dna - blood |
1 |
|
dosing |
1 |
|
drug administration schedule |
1 |
|
drugs, chinese herbal - adverse effects - therapeutic use |
1 |
|
dysmenorrhea |
1 |
|
editorial |
1 |
|
effectiveness |
1 |
|
embryo banking |
1 |
|
emergencies |
1 |
|
emergency oral contraception |
1 |
|
emotions |
1 |
|
endometrial scratching |
1 |
|
endometrium biopsy |
1 |
|
evidence-based medicine |
1 |
|
excessive response |
1 |
|
factorial design |
1 |
|
female infertility |
1 |
|
fetal dna |
1 |
|
fixed protocol |
1 |
|
follicle stimulating hormone - administration & dosage - adverse effects - therapeutic use |
1 |
|
genetic testing |
1 |
|
genital diseases, female - therapy |
1 |
|
genital diseases, male - therapy |
1 |
|
globins - genetics |
1 |
|
health status |
1 |
|
hydrosalpinges |
1 |
|
hyperhomocysteinemia |
1 |
|
hyperinsulinemic-euglycemic clamp |
1 |
|
hypoglycemic agents - administration and dosage - adverse effects - therapeutic use |
1 |
|
hysterectomy - adverse effects |
1 |
|
imprint |
1 |
|
individual patient data meta-analysis |
1 |
|
infertility trial |
1 |
|
infertility, female - surgery |
1 |
|
infertility, male - drug therapy - etiology - prevention and control - therapy |
1 |
|
infertility, male - therapy |
1 |
|
ivf add-on |
1 |
|
ivf adjunct |
1 |
|
ivf outcome prediction |
1 |
|
laparoscopic tubal ligation |
1 |
|
laparoscopy - adverse effects |
1 |
|
levonorgestrel - administration & dosage |
1 |
|
lidocaine - administration & dosage |
1 |
|
live birth rates |
1 |
|
luteinizing hormone - administration & dosage - therapeutic use |
1 |
|
massage |
1 |
|
maternal plasma |
1 |
|
maternal-fetal exchange |
1 |
|
medicine, east asian traditional - adverse effects |
1 |
|
menopause |
1 |
|
meta-analysis |
1 |
|
meta-analysis as topic |
1 |
|
microcoil |
1 |
|
mifepristone - administration & dosage |
1 |
|
misoprostol dose and route |
1 |
|
modification |
1 |
|
modified delphi method |
1 |
|
modified nominal group technique |
1 |
|
myomectomy |
1 |
|
ovarian hyperstimulation syndrome |
1 |
|
ovarian hyperstimulation syndrome - chemically induced |
1 |
|
ovarian reserve tests |
1 |
|
ovulation - drug effects - physiology |
1 |
|
pain, postoperative - drug therapy |
1 |
|
personalized protocol |
1 |
|
polycystic ovary syndrome - blood - diagnosis - drug therapy - physiopathology |
1 |
|
polycystic ovary syndrome - complications - physiopathology - psychology |
1 |
|
por |
1 |
|
pregnancy and obstetric outcomes |
1 |
|
progestin-primed ovarian stimulation |
1 |
|
puregon® |
1 |
|
qi gong |
1 |
|
rct |
1 |
|
reactive oxygen species |
1 |
|
recombinant fsh |
1 |
|
recombinant proteins - administration & dosage - adverse effects - pharmacology |
1 |
|
recombinant proteins - administration & dosage - adverse effects - therapeutic use |
1 |
|
reporting |
1 |
|
reproductive outcomes |
1 |
|
review |
1 |
|
risk factors |
1 |
|
safety |
1 |
|
second-hand smoke |
1 |
|
sex hormones |
1 |
|
sexual dysfunction |
1 |
|
sf-36 |
1 |
|
sham acupuncture |
1 |
|
spontaneous abortion |
1 |
|
standard incubation |
1 |
|
statistical analysis approach |
1 |
|
systematic review |
1 |
|
tai chi |
1 |
|
time to live birth |
1 |
|
total dna |
1 |
|
treatment add-on |
1 |
|
uterine hemorrhage - diagnosis |
1 |
|
uterine myomectomy - adverse effects |
1 |
|
world health organization |
1 |
|
wound healing - physiology |
1 |
|
x-ray surveillance |
1 |
|
yoga |
1 |
